HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

WCID 2025

Tree shrew: A new primate-like small animal for EBV research

Hirotomo Dochi, Speaker at Infectious Disease Conference
Louisiana Cancer Research Center, United States
Title : Tree shrew: A new primate-like small animal for EBV research

Abstract:

Epstein-Barr virus (EBV) is implicated in a wide range of human malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, and gastric carcinoma. However, progress in elucidating the mechanisms of EBV-associated oncogenesis has been hampered by the absence of an in vivo model that accurately recapitulates human infection. In this study, we propose the tree shrew as a physiologically relevant and genetically tractable animal model for EBV research. Owing to their close evolutionary relationship to primates and a human-like immune system, tree shrews offer unique advantages for studying EBV biology in vivo. Our preliminary data demonstrate that EBV can successfully infect tree shrews, establish latency, and undergo lytic reactivation—mirroring key aspects of human EBV infection. These results represent a critical advancement in overcoming the species barrier in EBV modeling. The tree shrew system provides a promising platform for dissecting EBV-host interactions, evaluating therapeutic interventions, and developing immunotherapeutic strategies against EBV-associated malignancies.

Biography:

Dr. Hirotomo Dochi earned his MD and PhD from Kanazawa University, Japan. He completed clinical training in otolaryngology and focused his PhD research on Epstein-Barr virus (EBV)-associated cancers. He is currently a postdoctoral fellow in Dr. Lin’s lab at Tulane University and the Louisiana Cancer Research Center, where he studies EBV reactivation and host-virus interactions. Dr. Dochi has received multiple honors, including a travel award to present his work on EBV infection models at the 2024 International Symposium on EBV & KSHV. His goal is to advance translational oncology through a combination of clinical and molecular research.

Newsletter

By signing up, you agree to join our mailing list to receive information and updates.

Watsapp